BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 31555945)

  • 21. Clinical outcomes in patients with diffuse large B cell lymphoma with a partial response to first-line R-CHOP chemotherapy: prognostic value of secondary International Prognostic Index scores and Deauville scores.
    Lee H; Kim YR; Kim SJ; Park Y; Eom HS; Oh SY; Kim HJ; Kang HJ; Lee WS; Moon JH; Won YW; Kim TS; Kim JS
    Ann Hematol; 2017 Nov; 96(11):1873-1881. PubMed ID: 28831584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era.
    Yang DH; Ahn JS; Byun BH; Min JJ; Kweon SS; Chae YS; Sohn SK; Lee SW; Kim HW; Jung SH; Kim YK; Kim HJ; Bom HS; Lee JJ
    Ann Hematol; 2013 Apr; 92(4):471-9. PubMed ID: 23238895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
    de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
    Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain glucose metabolism in diffuse large B-cell lymphoma patients as assessed with FDG-PET: impact on outcome and chemotherapy effects.
    Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
    Acta Radiol; 2016 Jun; 57(6):733-41. PubMed ID: 26297729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Kang HJ; Lee HH; Jung SE; Park KS; O JH; Jeon YW; Choi BO; Cho SG
    PLoS One; 2020; 15(9):e0238807. PubMed ID: 32960887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
    Chen-Liang TH; Martín-Santos T; Jerez A; Rodríguez-García G; Senent L; Martínez-Millán C; Muiña B; Orero M; Teruel A; Martín A; Gómez-Espuch J; Kennedy K; Benet C; Raya JM; Fernández-González M; de la Cruz F; Guinot M; Villegas C; Ballester I; Baile M; Moya M; López-Jiménez J; Frutos L; Navarro JL; Uña J; Fernández-López R; Igua C; Contreras J; Sánchez-Vañó R; Cozar MDP; Tamayo P; Mucientes J; Sánchez-Blanco JJ; Pérez-Ceballos E; Ortuño FJ
    Cancer Med; 2017 Nov; 6(11):2507-2514. PubMed ID: 28960797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-derived tumor metrics predict DLBCL response and progression-free survival.
    Islam P; Goldstein J; Flowers CR
    Leuk Lymphoma; 2019 Aug; 60(8):1965-1971. PubMed ID: 30714446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment.
    González-Barca E; Canales M; Cortés M; Vidal MJ; Salar A; Oriol A; Bargay J; Bello JL; Sánchez JJ; Tomás JF; Donato E; Ferrer S; Caballero D;
    Nucl Med Commun; 2013 Oct; 34(10):946-52. PubMed ID: 23880897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Value of
    Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
    Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma after radioimmunotherapy using 131I-rituximab as consolidation therapy.
    Choi JH; Lim I; Byun BH; Kim BI; Choi CW; Kang HJ; Shin DY; Lim SM
    PLoS One; 2022; 17(9):e0273839. PubMed ID: 36156599
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of CT-Based Measurements into Surveillance PET/CT in Patients with Diffuse Large B Cell Lymphoma.
    Lavi N; Shapira G; Zilberlicht A; Benyamini N; Farbstein D; Dann EJ; Bar-Shalom R; Avivi I
    Isr Med Assoc J; 2016 Jul; 18(7):411-417. PubMed ID: 28471564
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Cottereau AS; Nioche C; Dirand AS; Clerc J; Morschhauser F; Casasnovas O; Meignan M; Buvat I
    J Nucl Med; 2020 Jan; 61(1):40-45. PubMed ID: 31201248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.
    Huang H; Xiao F; Han X; Zhong L; Zhong H; Xu L; Zhu J; Ni B; Liu J; Fang Y; Zhang M; Shen L; Wang T; Liu J; Shi Y; Chen Y; Zheng L; Liu Q; Chen F; Wang J
    Nucl Med Commun; 2016 Jul; 37(7):689-98. PubMed ID: 27244584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies.
    Vassilakopoulos TP; Papageorgiou SG; Angelopoulou MK; Chatziioannou S; Prassopoulos V; Karakatsanis S; Arapaki M; Mellios Z; Sachanas S; Kalpadakis C; Katodritou E; Leonidopoulou T; Kotsianidis I; Hatzimichael E; Kotsopoulou M; Dimou M; Variamis E; Boutsis D; Terpos E; Michali E; Karianakis G; Tsirkinidis P; Vadikolia C; Poziopoulos C; Pigaditou A; Vrakidou E; Siakantaris MP; Kyrtsonis MC; Symeonidis A; Anargyrou K; Papaioannou M; Chatziharissi E; Vervessou E; Tsirogianni M; Palassopoulou M; Gainaru G; Mainta C; Tsirigotis P; Assimakopoulou T; Konstantinidou P; Papadaki H; Dimopoulos MA; Pappa V; Karmiris T; Roussou P; Datseris I; Panayiotidis P; Konstantopoulos K; Pangalis GA; Rondogianni P
    Ann Hematol; 2021 Sep; 100(9):2279-2292. PubMed ID: 33523289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.